Viskase Holdings, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| READ RANDOLPH C | — | Purchase | 15,000 | $0.13 | $1,950 | 115,450 | Jun 16, 2023 |
| Xstelos Corp. | — | Sale | 50,000 | $0.39 | $19,500 | 350,000 | Aug 13, 2021 |
| READ RANDOLPH C | — | Purchase | 50,000 | $0.16 | $8,000 | 100,450 | Nov 16, 2020 |
| Bleznick Jordan | — | Purchase | 100,000 | $0.15 | $15,000 | 100,000 | Nov 13, 2020 |
| ICAHN CARL C | — | X | 39,277 | — | — | 39,277 | Oct 9, 2020 |
| COUCHMAN JONATHAN | — | Sale | 25,000 | $0.19 | $4,750 | 1,590,194 | Aug 24, 2020 |
| Couchman Family Fund | — | Purchase | 506,292 | $0.20 | $101,258 | 2,100,524 | Aug 5, 2020 |
| Xstelos Corp. | — | Purchase | 469,551 | $0.14 | $65,737 | 472,479 | Mar 26, 2020 |
| Couchman Family Fund | — | Purchase | 2,678 | $0.14 | $375 | 2,928 | Mar 25, 2020 |
| COUCHMAN JONATHAN | — | Purchase | 500 | $0.25 | $125 | 4,707,666 | Feb 11, 2019 |
| COUCHMAN JONATHAN | — | Purchase | 312,523 | $0.27 | $84,381 | 1,559,523 | Dec 20, 2018 |
| Couchman Family Fund | — | Purchase | 112 | $0.26 | $29 | 4,130,224 | Jul 30, 2018 |
| ICAHN CARL C | — | Purchase | 694,023 | $0.41 | $284,549 | 6,598,886 | Nov 28, 2016 |
| ICAHN CARL C | — | X | 694,023 | — | — | 6,598,886 | Nov 28, 2014 |
| LEBUHN ROBERT | — | Sale | 21,119 | $1.69 | $35,691 | 42,189 | Sep 17, 2013 |
| Rackear Andrew D. | VP and General Counsel | Award / Grant | 4,686 | — | — | 78,019 | Jan 23, 2013 |
| Buchbinder Aby | VP, Clinical Development | Award / Grant | 3,748 | — | — | 79,246 | Jan 23, 2013 |
| Conover Charles | SVP, R&D Program Management | Award / Grant | 2,343 | — | — | 74,793 | Jan 23, 2013 |
| HEBARD GEORGE | Interim PEO and Interim COO | Award / Grant | 24,500 | — | — | 43,237 | Nov 7, 2012 |
| LEBUHN ROBERT | — | Sale | 5,820 | $6.58 | $38,296 | 98,115 | Aug 14, 2012 |
| LEBUHN ROBERT | — | Sale | 1,933 | $6.58 | $12,719 | 103,935 | Aug 10, 2012 |
| Young Richard A | — | Award / Grant | 10,669 | — | — | 30,231 | Jul 2, 2012 |
| SALISBURY ROBERT C | — | Award / Grant | 10,669 | — | — | 67,707 | Jul 2, 2012 |
| LEBUHN ROBERT | — | Award / Grant | 10,669 | — | — | 105,868 | Jul 2, 2012 |
| Deuel Thomas | — | Award / Grant | 10,669 | — | — | 32,231 | Jul 2, 2012 |
| Mulligan Richard | — | Award / Grant | 18,670 | — | — | 49,064 | Jul 2, 2012 |
| DENNER ALEXANDER J | — | Award / Grant | 21,338 | — | — | 60,620 | Jul 2, 2012 |
| HEBARD GEORGE | Interim PEO and Interim COO | Purchase | 5,000 | $6.88 | $34,400 | 18,737 | Jun 20, 2012 |
| Rackear Andrew D. | VP and General Counsel | Sale | 1,614 | $6.81 | $10,991 | 56,720 | Jun 5, 2012 |
| Conover Charles | SVP, R&D Program Management | Sale | 25,000 | $6.78 | $169,500 | 57,213 | Jun 5, 2012 |
| Daly Timothy | VP, Controller and PAO | Award / Grant | 8,000 | — | — | 8,000 | Mar 28, 2012 |
| Young Richard A | — | Sale | 2,000 | $6.92 | $13,840 | 19,562 | Mar 15, 2012 |
| HEBARD GEORGE | — | Award / Grant | 13,737 | — | — | 13,737 | Feb 27, 2012 |
| Buchbinder Aby | VP, Clinical Development | Award / Grant | 4,000 | — | — | 58,015 | Jan 17, 2012 |
| Conover Charles | SVP, R&D Program Management | Award / Grant | 10,000 | — | — | 82,213 | Jan 17, 2012 |
| Rackear Andrew D. | VP and General Counsel | Award / Grant | 10,000 | — | — | 58,334 | Jan 17, 2012 |
| Greenberger Lee M | VP, Research | Award / Grant | 3,500 | — | — | 36,146 | Jan 17, 2012 |
| Stancic Ana | Executive VP, COO, PEO, CFO | Award / Grant | 45,000 | — | — | 70,000 | Jan 17, 2012 |
| Stancic Ana | Executive VP, COO, PEO, CFO | Award / Grant | 45,000 | — | — | 70,000 | Nov 17, 2011 |
| Rackear Andrew D. | VP and General Counsel | Sale | 3,766 | $6.68 | $25,157 | 48,334 | Nov 10, 2011 |
| Buchbinder Aby | VP, Clinical Development | Sale | 2,700 | $7.06 | $19,062 | 54,015 | Nov 8, 2011 |
| Greenberger Lee M | VP, Research | Tax Withholding | 591 | $8.33 | $4,923 | 32,646 | Sep 15, 2011 |
| del Campo Ralph | COO and Princ. Exec. Officer | Tax Withholding | 886 | $8.33 | $7,380 | 204,633 | Sep 15, 2011 |
| Rackear Andrew D. | VP and General Counsel | Tax Withholding | 2,067 | $8.33 | $17,218 | 52,100 | Sep 15, 2011 |
| Buchbinder Aby | VP, Clinical Development | Tax Withholding | 2,952 | $8.33 | $24,590 | 56,715 | Sep 15, 2011 |
| Buchbinder Aby | VP, Clinical Development | Award / Grant | 8,000 | — | — | 59,667 | Aug 12, 2011 |
| Rackear Andrew D. | VP and General Counsel | Award / Grant | 10,000 | — | — | 54,167 | Aug 12, 2011 |
| del Campo Ralph | COO and Princ. Exec. Officer | Award / Grant | 35,000 | — | — | 204,633 | Aug 12, 2011 |
| DENNER ALEXANDER J | — | Award / Grant | 14,764 | — | — | 39,282 | Jul 1, 2011 |
| Deuel Thomas | — | Award / Grant | 7,382 | — | — | 21,562 | Jul 1, 2011 |